Read More

Alterity Therapeutics Announced Monday, Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer’s Disease

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced that the composition of matter patent previously allowed by the United States Patent and Trademark Office (USPTO) has now been granted. The patent, entitled "Compounds for and methods of treating diseases" (No. 11,603,364), covers more than 100 novel compounds with an acyl hydrazone (AH) structure and provides 20 years of exclusivity.

ATHE